Randomized Trial of Warfarin Nomograms

  1. Michael J. Kovacs, MD, FRCPC; and
  2. Philip S. Wells, MD, FRCPC, MSc
  1. From London Health Sciences Centre, London, Ontario N6A 4G5, Canada, and Ottawa Hospital—Civic Campus; Ottawa, Ontario K1Y 4E9, Canada.

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    IN RESPONSE:

    We thank all of the correspondents for the interest in our article, which has initiated a strong and emotional debate. Given the …

    « Previous | Next Article »Table of Contents